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STUDY PROTOCOL Open Access
Empagliflozin in heart failure patients with
reduced ejection fraction: a randomized
clinical trial (Empire HF)
Jesper Jensen1,7* , Massar Omar2,8, Caroline Kistorp3,7, Mikael Kjær Poulsen2, Christian Tuxen4, Ida Gustafsson4,7,
Lars Køber5,7, Finn Gustafsson5,7, Emil Fosbøl5, Niels Eske Bruun6,7,9, Lars Videbæk2, Peter Hartmund Frederiksen2,
Jacob Eifer Møller2,8 and Morten Schou1,7
Abstract
Background: Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that
sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in
patients without HF. Ongoing event-driven trials are investigating whether the same effect is present in patients
with well-defined HF. The mechanism behind the effect of SGLT2 inhibitors in patients with T2D and the potential
effect in patients with overt HF is presently unknown.
Methods: This is a randomized, double-blinded, placebo-controlled, parallel group, clinical trial including HF patients
with reduced left ventricular ejection fraction (HFrEF) with an ejection fraction ≤ 40% on optimal therapy recruited
from specialized HF clinics in Denmark. The primary aim is to investigate the effect of the SGLT2 inhibitor empagliflozin
on N-terminal pro-brain natriuretic peptide (NT-proBNP). Secondary endpoints include cardiac biomarkers, function and
hemodynamics, metabolic and renal parameters, daily activity level, and quality of life. Patients are assigned 1:1 to 90
days treatment with empagliflozin 10mg daily or placebo. Patients with T2D are required to be on recommended
doses of anti-glycemic therapy with a hemoglobin A1c (HbA1c) of 6.5–10.0% (48–86mmol/mol). To show a between-
group difference in the change of NT-proBNP of 30%, a total of 189 patients will be included.
Discussion: The Empire HF trial will elucidate the effects and modes of action of empagliflozin in HFrEF patients with
and without T2D and provide important mechanistic data which will complement ongoing event-driven trials.
Trial registration: Clinicaltrialsregister.eu, EudraCT Number 2017-001341-27. Registered on 29 May 2017.
ClinicalTrials.gov, NCT03198585. Registered on 26 June 2017.
Keywords: Heart failure, SGLT2 inhibitors, Mechanism, Mode of action, NT-proBNP, Daily activity level, Cardiac function,
Metabolic endpoints, Renal endpoints, Quality of life
Background
Within recent years, attention to heart failure (HF) care in
patients with type 2 diabetes (T2D) has increased markedly
after results from three randomized clinical trials (RCT)
evaluating the effect of sodium-glucose co-transporter 2
(SGLT2) inhibitors [1–3]. In these safety trials, it was ob-
served that three different SGLT2 inhibitors could prevent
development of HF and prolong life in patients with T2D.
Recently, the results have been replicated in real life [4, 5].
The mechanism behind these observations are poorly
understood and while several hypotheses have been pro-
posed, data are lacking [6–9].
In the Empagliflozin, Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
trial, the Canagliflozin Cardiovascular Assessment Study
(CANVAS) program, and the Dapagliflozin Effect on Car-
diovascular Events-Thrombolysis in Myocardial Infarction
58 (DECLARE-TIMI 58) trial, 10–14% of the included
patients had a reported history of HF at baseline and a
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significant subgroup effect was observed with a reduction
in the composite endpoint of hospitalization for HF or
cardiovascular death in patients treated with empagliflozin,
canagliflozin, and dapagliflozin, respectively [3, 10, 11].
However, HF was neither well-defined nor described in
these trials; central information such as whether the pa-
tients with reported HF had preserved (HFpEF) or reduced
(HFrEF) ejection fraction is unknown. The possible benefi-
cial effects of SGLT2 inhibitors are unknown in patients
without T2D but the primary action in the kidneys – in-
duction of glucosuria and natriuresis – have been demon-
strated in individuals without T2D [12]. Proposed derived
mechanisms potentially explaining the observed cardiovas-
cular benefits of SGLT2 inhibitors include a proportionally
larger reduction in the extracellular volume (ECV) than in
the plasma volume (PV) [13, 14], leading to a reduced
preload, left ventricular (LV) filling pressure, and LV wall
stress, the latter being the primary driver for N-terminal
pro-brain natriuretic peptide (NT-proBNP) production.
Thereby, a net effect of decreased NT-proBNP levels,
which is associated with a decreased mortality risk in HF
populations, is plausible [15, 16] and a decrease of 30% in
NT-proBNP has previously been shown to be clinically
significant in this population [17]. Other proposed derived
mechanisms of SGLT2 inhibitors supporting beneficial car-
diovascular effects in HF patients include a favorable shift
in glucose and fat metabolism towards increased ketone
substrate use [18, 19], renoprotective effects with changes
in intrarenal hemodynamics, uricosuria and reduced
albuminuria [7], and direct cardiac effects with remodeling
of the myocardium ultimately leading to an improvement
in the ventricular systolic function [9].
To increase the understanding of the cardiovascular
effects of SGLT2 inhibitors, we are evaluating the effect of
the SGLT2 inhibitor empagliflozin in HFrEF patients with
a left ventricular ejection fraction (LVEF) ≤ 40% on cardiac
biomarkers, function and hemodynamics, metabolic and
renal parameters, and daily activity level and quality of life.
The results of the Empire HF trial will complement the re-
sults from ongoing event-driven trials and may provide
pathophysiological insight into the effect of this new group
of drugs in HFrEF patients. Here, we present the protocol
for the Empire HF trial. A checklist in accordance with the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) for the reporting of the protocol is
available (Additional file 1).
Methods
Study hypotheses
The study hypotheses are presented in Fig. 1. The main hy-
pothesis of the Empire HF trial is that 90 days treatment
with empagliflozin 10mg once daily compared with placebo
reduces NT-proBNP in stable HFrEF patients on optimal
therapy. An exploratory hypothesis is that the treatment is
associated with an increase in the daily activity level and
secondary hypotheses include that the treatment: reduces
the amount of visceral fat, reduces insulin resistance, and in-
creases supply of ketones to the heart (Metabolic hypoth-
esis); maintains glomerular filtration rate (GFR) and reduces
estimated extracellular volume (eECV), estimated plasma
volume (ePV), uric acid, and urinary excretion of albumin
(Renal hypothesis); reduces plasma concentrations of mid-
region pro-peptide of adrenomedullin (MR-proADM)
and high-sensitivity cardiac troponin I (hs-cTnI) (Car-
diac Biomarker hypothesis); improves left ventricular
global longitudinal strain (LV-GLS) and LVEF at rest
and during pharmacological stress (Cardiac function
hypothesis); reduces the pulmonary capillary wedge
pressure (PCWP) to cardiac index (CI) ratio during
sub-maximal exercise and improves LV contractile
reserve (Hemodynamic hypothesis); improves health-
related quality of life (Quality of life hypothesis).
Primary objective
The primary objective of the study is to assess the effect
of empagliflozin on NT-proBNP.
Secondary objectives
An exploratory objective of the study is to assess the effect
of empagliflozin on daily activity level. Secondary objec-
tives include assessment of the effects on body compos-
ition, glucose metabolism, and ketones; GFR, eECV, ePV,
urid acid, and urine albumin to creatinine ratio (UACR);
cardiac biomarkers including MR-proADM and hs-cTnI;
LV diastolic and systolic function at rest and during low-
dose dobutamine infusion with echocardiography; central
invasive hemodynamics at rest and during exercise; and
health-related quality of life.
Study design
Investigator-initiated, double-blinded, placebo-controlled,
parallel group RCT. Two experimental sites and five
recruiting sites.
Study population
Stable outpatients with HFrEF on optimal therapy in ac-
cordance with most recent European and national guide-
lines [20]. It is expected that 20% of the patients have
known T2D and that an additional 30% of the patients
will have a diagnosis of new onset T2D or impaired glu-
cose tolerance based on an oral glucose tolerance test
(OGTT) at the randomization visit [21, 22].
Primary endpoint
Between-group difference in the change of plasma con-
centrations of NT-proBNP from baseline to 90 days.
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Secondary endpoints
All the below secondary endpoints will be quantified as the
between-group difference in the change of the given end-
point from baseline to 90 days. As an exploratory endpoint,
the amount of daily average accelerometer units is chosen,
measured by patient-worn accelerometers [23]. Secondary
endpoints include: visceral fat assessed by whole-body
dual-energy X-ray absorptiometry (DXA) scan [24]; ePV
assessed by hematocrit and hemoglobin [25]; glucose
metabolism assessed by OGTT including assessment of
insulin sensitivity quantified with the Matsuda index [21];
ketone supply to the heart assessed by measuring beta-
hydroxybutyrate [26, 27]; renal function assessed by meas-
uring GFR and eECV with chromium-51 labelled ethylene-
diamine tetraacetic acid (51Cr-EDTA) clearance [28, 29];
uric acid and UACR [30, 31]; cardiac biomarkers assessed
by measuring MR-proADM and hs-cTnI [32, 33]; cardiac
systolic and diastolic function including LV-GLS and LVEF
assessed by transthoracic echocardiography at rest and dur-
ing low-dose dobutamine stress with a dosage of 20 μg/kg/
min [34, 35]; cardiac hemodynamics during sub-maximal
exercise assessed by right heart catheterization (RHC)
including PCWP/CI index and LV contractile reserve [36];
and health-related quality of life assessed by the question-
naires Kansas City Cardiomyopathy Questionnaire (KCCQ)
and EuroQol 5-dimension 5-level (EQ-5D-5 L) question-
naire [37, 38].
Assessment and randomization
The schedule of enrolment, interventions, and assess-
ments in accordance with SPIRIT is outlined in Fig. 2.
At the screening visit, informed consent is obtained by
an investigator or trained study nurse, baseline charac-
teristics assessed based on the medical record and con-
firmed in consultation with the patient, and eligibility
confirmed with fulfilment of all inclusion criteria and no
exclusion criteria. At the following randomization visit,
patients are randomized 1:1 regarding both the primary
and secondary endpoints. To ensure both safety assess-
ment, adherence, and complete follow-up, follow-up
assessments are carried out as two telephone contacts, a
control visit, and an end-of-study visit. The allocated
treatment of individual patients may be discontinued or
modified based on the patient’s decision, a positive preg-
nancy test, severe non-adherence, or if the investigators
assess that further treatment is contraindicated because
Fig. 1 Empire HF hypotheses. SGLT2 sodium-glucose cotransporter 2, GFR glomerular filtration rate, eECV estimated extracellular volume, ePV estimated
plasma volume, UACR urine albumin to creatinine ratio, NT-proBNP N-terminal pro-brain natriuretic peptide, MR-proADM mid-region pro-peptide of
adrenomedullin, hs-cTNI high-sensitivity cardiac troponin I, LV left ventricular, KCCQ Kansas City cardiomyopathy questionnaire, EQ-5D-5 L EuroQol
5-dimension 5-level
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of adverse events (AEs) or other safety reasons. If possible,
patients who discontinue or deviate from the protocol will
be followed up regarding all endpoints. Strategies to im-
prove adherence include information at both the screening
and randomization visit regarding correct drug administra-
tion and the patients are encouraged to use a medication
diary or pill boxes during the study. At all planned contacts
during the treatment period, the patients are asked whether
they adhere to the correct drug administration. At the end
of the study visit, excess tablets of the investigational prod-
uct (IP) are returned for drug accountability.
Inclusion and exclusion criteria
Inclusion and exclusion criteria are presented in Table 1.
Both HF patients with and without T2D are included. Pa-
tients with known T2D will be treated in accordance with
European and national guidelines and will be on recom-
mended, stable dose(s) of anti-glycemic drug(s) for 30 days
before randomization and no additional anti-glycemic
drugs will be added during the study period. Patients with
new onset T2D at the randomization visit will not receive
additional anti-glycemic treatment during the study period.
Regarding treatment for HF, patients will be on optimal,
stable medical treatment in accordance with European
guidelines for 30 days before randomization. If indicated, a
device will be implanted before randomization in accord-
ance with national guidelines. For implantation of a cardio-
verter defibrillator (ICD) and cardiac resynchronization
therapy (CRT), a minimum period of 30 and 90 days will
be obtained between implantation and randomization,
respectively. During the study period, conventional HF
therapy will only be changed if side effects are suspected.
Schedule of enrolment, interventions, and assessments
Eligible patients will undergo the study visits presented in
Fig. 2. In addition, unlimited access to telephone and email
service is available and, if considered necessary, unsched-
uled visits during the study period through four weeks after
the end-of-study visit is planned. Follow-up will be per-
formed by investigators, sub-investigators, and study nurses
educated in the specialized treatment of HF patients and
who are trained in the study protocol. Important protocol
Fig. 2 Schedule of enrolment, interventions, and assessments in accordance with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT). #Only performed in the patients enrolled at Herlev-Gentofte Hospital. *Only performed in a sub-group of the patients
enrolled at Odense University Hospital. ECG electrocardiogram, OGTT oral glucose tolerance test, DXA dual-energy X-ray absorptiometry, 51Cr-
EDTA chromium-51 labeled ethylenediamine tetra-acetic acid. AE adverse event, SAE severe adverse event, IP investigational product
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modifications will be communicated to relevant parties in-
cluding regulators, the ethical review board, investigators,
trial participants, trial registries, and journals.
Statistical analyses
Intention-to-treat (ITT) analyses will be applied as the
primary analysis. Analysis of the primary endpoint is
comparison of the between-group difference in the change
of NT-proBNP from baseline to 90 days. The primary end-
point will be analyzed using analysis of covariance
(ANCOVA), with treatment as a fixed factor, the baseline
NT-proBNP level as a covariate and with adjustment for
age, sex, history of T2D, and site of randomization. Miss-
ing data in the primary analysis will be estimated using im-
putation. Approximately half the patients will have either
known T2D, new-onset T2D, or impaired glucose toler-
ance. Test for interaction between treatment, abnormal
glucose tolerance, and all the specified endpoints (prede-
fined sub-group analyses) will be performed. Log trans-
formation will be performed if assumption of normality is
not met. After log transformation, the parameter will be
further tested for normality as indicated. A two-tailed p
value ≤ 0.05 is considered statistically significant. Normally
distributed variables will be presented as mean ± standard
deviation (SD) and skewed distributed variables as median
and interquartile range [IQR]. Comparisons between treat-
ment and placebo group will be performed by an unpaired
two sample t-test, Mann–Whitney test, or χ2 test as
appropriate.
Sample size
Primary endpoint: Based on data from a previous study, it
is expected that a reduction in NT-proBNP of 30% is clin-
ically significant [17]. To test the primary hypothesis that
empagliflozin 10mg daily compared with placebo reduces
NT-proBNP with 30% (SD of 70%) with a power of 0.80
and a significance level of 0.05, a total of N = 172 patients
in the main study is required. To allow for dropouts, the
final total sample size is planned to be 189 patients.
Low dose dobutamine sub-study: To detect a clinically
significant decrease in LV-GLS of 20% (SD of 30%) in
patients treated with empagliflozin compared with pla-
cebo in this secondary endpoint with a power of 0.80
and a significance level of 0.05, a total of 72 patients are
required. To allow for dropouts, N = 119 patients are
planned to be enrolled at Herlev-Gentofte Hospital in
this sub-study (Cardiac function hypothesis).
Hemodynamic sub-study: PCWP is expected to increase
to 32 ± 8mmHg and CI to 5.0 ± 1.4 L/min/m2 with exer-
cise, with a PCWP/CI ratio equal to 6.4 ± 1.4. To detect a
decrease of 20% in patients treated with empagliflozin
compared with placebo in this secondary endpoint with a
power of 0.80 and a significance level of 0.05, a total of 61
patients are required. To allow for dropouts, N = 70 pa-
tients are planned to be enrolled at Odense University
Hospital in this sub-study (Hemodynamic hypothesis).
In all the other sub-studies, the sample size is a conse-
quence of the main study on NT-proBNP and confidence
intervals will be evaluated critically. Based on previous
studies it is expected to observe a possible significant
difference with the used sample sizes [24, 39].
Blinding
Both patients and investigators are blinded to the treatment
allocation. The IP of empagliflozin 10mg tablets or match-
ing placebo are produced by the Glostrup Pharmacy as
identical white capsules delivered to each patient as a con-
tainer with 90 capsules. The Glostrup Pharmacy is a public
pharmacy which is independent of the steering committee
and study centres. The IP is produced and controlled in
accordance with the requirements in the Commission
Directive 2003/94/EC of 8 October 2003 laying down the
principles and guidelines of good manufacturing practice
and in compliance with Good Medical Practice (GMP). The
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Optimal heart failure therapy in
accordance with European and
national guidelines
CRT-D/−P implanted < 90 days
LVEF≤ 0.40 Uncorrected severe valvular
disease
eGFR > 30mL/min/1.73 m2 Non-compliance
BMI < 45 kg/m2 Use of metalozone
NYHA class I–III NYHA class IV
Age > 18 years Age > 85 years
Dementia
Admission for HF < 30 days
If T2D – optimal treatment in
accordance with European
and national guidelines
Admission for hypoglycemia
< 12months
If T2D – stable doses of
anti-glycemic treatment
for 30 days
Known sustained VT
If T2D – HbA1c 6.5–10.0% Symptomatic hypotension
and systolic BP < 95 mmHg
Unable to perform an exercise
test
Immobilization
Pregnancy
Participation in other medical
trials
Previous intolerance of
Empagliflozin or excipients
LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate,
BMI body mass index, NYHA New York Heart Association, T2D type 2 diabetes,
HbA1c hemoglobin A1c, CRT-D/−P cardiac resynchronization therapy with
defibrillator (−D) or without defibrillator (−P), HF heart failure, VT ventricular
tachycardia, BP blood pressure
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allocation sequence is generated by Glostrup Pharmacy
using computer-generated random numbers in blocks of
10. Treatment may be unblinded in medical emergencies
during the study if the investigators deem it necessary.
Unblinding during the study period may be made individu-
ally and is performed by telephone contact from the inves-
tigators to Glostrup Pharmacy, where the allocation
sequence is stored. A copy of the allocation sequence is
concealed in opaque, sealed envelopes which are stored in
a locked cabinet in the sponsor’s office. Data analysis will
be blinded to the investigators regarding primary, explora-
tory, and secondary endpoints (triple blinding).
Study organization
Study centers and time schedule
Patients are recruited from specialized HF clinics at five
sites in Denmark (Herlev-Gentofte Hospital, Odense Uni-
versity Hospital, Bispebjerg-Frederiksberg Hospital, Rig-
shospitalet, and Amager-Hvidovre Hospital). Screening,
randomization, and protocol-specified assessments are
performed at two sites (Herlev-Gentofte Hospital and
Odense University Hospital). All assessments are per-
formed at both sites, except RHC, which is only performed
in patients randomized at Odense University Hospital and
DXA-scan, and 51Cr-EDTA clearance and dobutamine
stress-echocardiography, which are only performed in pa-
tients randomized at Herlev-Gentofte Hospital (Fig. 2). The
study protocol and the used methods are routine proce-
dures at the performing sites [40, 41]. At present (Decem-
ber 2018), 112 patients have been randomized and
enrolment follows the planned schedule. It is expected that
the last patient’s last visit will be in October 2019.
Steering committee
The steering committee consists of JJ, MO, CK, MKP,
CT, IG, LK (chair), FG, EF, NEB, LV, JEM, and MS. The
steering committee is responsible for the design, moni-
toring, reporting, and publication of the trial. Primary
investigators are MS at Herlev-Gentofte Hospital and
JEM at Odense University Hospital. The steering com-
mittee will have access to the final trial dataset.
Monitoring and data collection
Data will be collected and stored using electronic case
report forms (eCRFs) constructed in the Research Elec-
tronic Data Capture (REDCap) system (Vanderbilt Uni-
versity ©2018). Corresponding source documents are
stored at the experimental sites in accordance with the
rules and regulations of the Danish Data Protection
Agency to ensure confidentiality. The study is monitored
by the GCP units at the University of Copenhagen and
the University of Southern Denmark based on a specific
monitoring plan. The GCP units are independent from
the steering committee.
Ethics and adverse events
The safety of the randomized patients will be monitored
continuously based on recording of AEs and severe adverse
events (SAEs) from signing the informed consent form
through four weeks after the end-of-study visit. The data
will be collected and recorded on standardized forms at
each contact. After the end-of-study visit, no planned con-
tacts are performed but patients are instructed to contact
the investigators if late-occurring AEs are suspected. These
data are reported to the relevant authorities in accordance
with applicable laws and International Conference of
Harmonization Good Clinical Practice (ICH-GCP) guide-
lines. An independent endocrinologist is the unblinded data
monitor and will evaluate the AEs and SAEs when half the
patients are enrolled and can make the final decision to ter-
minate the trial based on these safety data. Previously, no
hypoglycemic events were observed when HF patients
without T2D were included in a trial at Herlev-Gentofte
Hospital evaluating the anti-glycemic drug Liraglutide [42].
Empagliflozin is approved for treatment of T2D. As the
mechanisms behind the cardioprotective effects of
empagliflozin are unknown, the steering committee
finds it ethically acceptable to test active medication
against placebo, instead of an active comparator. There
are ongoing RCTs evaluating SGLT2 inhibitors in
HFrEF patients both with and without T2D (Empagli-
flozin Outcome Trial in Patients with Chronic Heart
Failure with Reduced Ejection Fraction [EMPEROR-Re-
duced], ClinicalTrials.gov Identifier NCT03057977;
Study to Evaluate the Effect of Dapagliflozin on the In-
cidence of Worsening Heart Failure or Cardiovascular
Death in Patients with Chronic Heart Failure [DAPA
HF], ClinicalTrials.gov Identifier NCT03036124). The
risk of significant side effects to empagliflozin is esti-
mated to be modest. Compensation to those patients
who suffer harm from study participation is set by the
public Patient Compensation Association in Denmark.
Biobank
A research biobank is established in relation to the trial,
where blood and urine samples are stored in coded form
for later analysis of biomarkers. After the analyses de-
clared in the protocol, the samples will be anonymized
and the research biobank will be discontinued in accord-
ance with the rules and regulations of the Danish Data
Protection Agency. Patients are informed about the re-
search biobank before signing the informed consent form.
Dissemination of results
The results of the study will be submitted to international
peer-reviewed scientific journals, irrespective of their out-
come, and the data will be made available to the public via
EudraCT (www.clinicaltrialsregister.eu) and www.clinical-
trials.gov. Positive, inconclusive, and negative results will
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be presented. Furthermore, the results will be presented at
scientific conferences as abstracts, oral presentations, and
posters. The steering committee will assess authorship eli-
gibility for the scientific papers related to the study based
on the recommendations of the International Committee
of Medical Journal Editors (ICMJE).
Conclusions and clinical implications
The anticipated results from ongoing randomized clinical
trials will decide whether SGLT2 inhibitors will be a future
treatment option in HFrEF patients. The Empire HF trial
will complement these event-driven trials with mechanistic
insight supporting clinicians and researchers in under-
standing the underlying mode of action of SGLT2 inhibi-
tors including whether the observed effect on clinical
outcomes is cardiac, renal, and/or metabolic, and whether
SGLT2 inhibitors have an impact on patient-centered end-
points including physical activity and quality of life.
Trial status
The study is currently recruiting and enrolling partici-
pants. Protocol version 5, 5 October 2018. Start of recruit-
ment: 29 June 2017. Approximate date when recruitment
will be completed: 31 October 2019.
Additional file
Additional file 1: Checklist for the reporting of study protocols in
accordance with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT). (DOCX 50 kb)
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